The effect of flurbiprofen on steady-state plasma lithium levels.
Pharmacotherapy
; 17(1): 113-20, 1997.
Article
em En
| MEDLINE
| ID: mdl-9017771
ABSTRACT
STUDY OBJECTIVE:
To evaluate the effects of flurbiprofen therapy on the pharmacokinetics of lithium.DESIGN:
Placebo-controlled, single-blind, crossover study.SETTING:
University-affiliated hospital. PATIENTS Eleven healthy women with bipolar disorder.INTERVENTIONS:
The subjects received therapeutic doses of lithium administered as an immediate-release capsule every 12 hours. In addition, they received one placebo tablet every 12 hours during phase I and flurbiprofen 100 mg every 12 hours during phase II of the study. MEASUREMENTS AND MAINRESULTS:
Steady-state pharmacokinetic parameters were measured for each phase. Lithium trough plasma concentration (Cmin) and area under the curve were statistically significantly increased (p < 0.05) when patients received flurbiprofen. Flurbiprofen also caused decreases in lithium clearance and 24-hour lithium urine excretion, although the changes did not reach statistical significance. Clinically significant increases in Cmin appeared to be associated with a greater than 1000-microgram/24 hour decrease in urinary excretion of prostaglandin E2.CONCLUSION:
Patients with clinically normal renal function may experience an increase in lithium levels with the initiation of flurbiprofen therapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Anti-Inflamatórios não Esteroides
/
Flurbiprofeno
/
Carbonato de Lítio
/
Antimaníacos
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Female
/
Humans
Idioma:
En
Revista:
Pharmacotherapy
Ano de publicação:
1997
Tipo de documento:
Article
País de afiliação:
Estados Unidos